The ColaLife packaging story (so far)26th DuPont Awards for Packaging Innovation
15-May-2014
Slash & Burn Agriculture | NE Zambia, 1985
Coca-Cola seems to get everywhere in developing countries, yet life-saving medicines don't. Why?
Our starting point
The humble telex machine, 1985
The mighty Facebook, May 2008
Sep 2010 | Cycle route - Boulogne to Biarritz
Sep 2010 | Cycle ride across France raised £6,000
Dec 2010 | Met Chris Griffin of PI Global at UnLtd event
2010 | Early model AidPods
2010 | Early model AidPods
May 2013 | The award-winning Kit Yamoyo
Our packaging partners
Our innovation drivers
Sharing and open innovation1Understanding customer needs2Building unlikely alliances3
The standard suppliers’ solution – the cardboard box
Mar 2012 | Finalised the Kit Yamoyo design
Kit Yamoyo• Attractive• ORS sachets are 200ml
Mar 2012 | Finalised the Kit Yamoyo design
Kit Yamoyo• Attractive• ORS sachets are 200ml• Packaging is also:
• A measuring device for the water
Mar 2012 | Finalised the Kit Yamoyo design
Kit Yamoyo• Attractive• ORS sachets are 200ml• Packaging is also:
• A measuring device for the water
• A mixing device
Mar 2012 | Finalised the Kit Yamoyo design
Kit Yamoyo• Attractive• ORS sachets are 200ml• Packaging is also:
• A measuring device for the water
• A mixing device• A storage device (the
soap tray is a lid)• A cup
Mar 2012 | Finalised the Kit Yamoyo design
>26kkits sold into the two remote rural trial areas in 12 months.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
4%Only 4% of kits went into Coca-Cola crates. It was the space in the market not the space in the crates that was important.
Our award-winning idea……
Our award-winning idea……what happened in practice
The screw-top
The screw-top The flexi-pack
14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points.
>26kkits sold into the two remote rural trial areas in 12 months.
45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.
2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.
93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.
4%Only 4% of kits went into Coca-Cola crates. It was the space in the market not the space in the crates that was important.
Thanks to our packaging partners
(none of this would have been possible without them)
Thanks to our Funders
The data contained in this presentation are unpublished and based on preliminary analysis of data from the ColaLife Operational Trial in Zambia (COTZ). Final calculations may vary and will be published in peer reviewed literature in due course.
In the interim, the following citation may be used: Ramchandani, R. et al. (2014). ColaLife Operational Trial Zambia (COTZ) Evaluation. Johns Hopkins Bloomberg School of Public Health, Baltimore.
Related correspondence should be sent to Rohit Ramchandani ([email protected]) and copied to Simon Berry ([email protected]).
A note on the data contained within this presentation
Awards | The Kit Yamoyo has won many global awards